Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,523 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,523 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the transaction, the chief executive officer now owns 191,163 shares in the company, valued at $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $419,712.68.
• On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The stock was sold at an average price of $105.16, for a total value of $277,412.08.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $122.40 on Friday. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54. The company has a 50-day moving average price of $123.30 and a 200 day moving average price of $110.36. The company has a market cap of $15.03 billion, a P/E ratio of -39.23 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same period last year, the firm earned ($0.97) EPS. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. Research analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NTRA. Leerink Partners upped their target price on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday. Morgan Stanley increased their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. UBS Group lowered their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Canaccord Genuity Group upped their price target on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, The Goldman Sachs Group raised their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Institutional Investors Weigh In On Natera

Several institutional investors have recently made changes to their positions in NTRA. Quent Capital LLC increased its holdings in shares of Natera by 3.2% in the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 99 shares in the last quarter. GAMMA Investing LLC grew its position in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the period. Moss Adams Wealth Advisors LLC increased its holdings in Natera by 5.4% in the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after buying an additional 135 shares in the last quarter. Quarry LP lifted its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Natera during the 2nd quarter worth approximately $28,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.